IBM Plunged After Issuing a Warning on the Software Sector. Time to Buy?

IBM shares fell 25% in one day after CEO Arvind Krishna said high hardware capex led companies to shift budgets away from software. Preliminary Q2 results showed revenue growth slowed to 1% y/y, with software growth down from 11% in Q1 to 5% in Q2 and infrastructure revenue declining 7% y/y. Despite the drawdown, the article notes IBM’s P/E is down to ~19 (multi-year low) and total returns have outperformed the S&P 500 under Krishna, with Red Hat growing 11% y/y and $2B of CHIPS Act-funded quantum foundry investment plus $10B planned over five years.

Analysis

The selloff is really a reset of IBM’s growth-duration premium, not a judgment on current earnings power. When enterprise buyers redirect spend from software to infrastructure, the first-order damage is to IBM’s recurring mix, but the second-order effect is worse: once software seat expansion stalls, renewal pricing power weakens and services attach rates can fade a quarter or two later. That makes this more than a one-quarter miss; the next 1-3 months likely hinge on whether management can show backlog quality and Red Hat retention are holding up despite the budget shift.

Competitive dynamics are mixed. Pure-play enterprise software names with higher growth expectations can absorb some of the same budget pressure, so this is a cautionary signal for ORCL, NOW, and ADBE if CIOs are prioritizing infrastructure over applications. On the other side, infrastructure-heavy beneficiaries of AI spending such as NVDA, ANET, and selected server/storage vendors may keep winning share of wallet even if software budgets stay soft. IBM’s own hardware arm is not a clean hedge here; if it cannot monetize the capex cycle, it loses the one offset that would have protected the multiple.

The contrarian point is that a lot of the bad news may now be in the stock. A sub-20x multiple is not cheap for a low-single-digit grower, but it is also not expensive if free cash flow remains resilient and buybacks stay aggressive. What would falsify the bearish setup is a quick re-acceleration in software growth or evidence that Red Hat is being used to defend share without margin dilution; absent that, the more likely path is range-bound performance with downside on any further guide-downs over the next 1-2 quarters.

Quantum remains a multi-year option value story, not a near-term valuation anchor. The market should discount it heavily until there is either third-party validation of commercial traction or meaningful revenue contribution; otherwise it functions more like a narrative support than a cash-flow driver. In the meantime, the key risk is that IBM’s capital intensity rises faster than its core software growth, which would keep the multiple compressed even if the broader tape stays constructive.

Key Decisions for Investors

• Short IBM into any post-selloff relief rally over the next 2-6 weeks; thesis is that multiple compression persists until software growth re-accelerates, with upside capped unless next quarter shows clear bookings improvement. Cover if IBM reclaims its pre-earnings valuation zone and software growth inflects back above low-double digits.
• Pair trade: long NVDA / short IBM for 1-3 months to express the budget-reallocation theme. NVDA captures infrastructure spend directly while IBM is exposed to software budget displacement; this is cleaner than a directional short on enterprise software alone.
• Watch ORCL and NOW for read-through risk over the next earnings cycle; if IBM’s slowdown is echoed in guide language or billings, trim exposure to high-multiple enterprise software. Falsifier: stable or improving net retention / RPO across the group.
• For long-only accounts, wait for evidence of software stabilization before adding IBM; the better entry is after the next quarter confirms Red Hat growth and margin discipline, not on the first bounce. Risk/reward is only attractive if the market stops pricing in a second leg of deceleration.
• Avoid treating IBM quantum spending as investable near-term alpha; it is a 6-18 month option with high execution risk. If you want quantum exposure, use a basket/watchlist approach rather than underwriting IBM’s core valuation on it.